Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
|Articles|January 1, 2003
Oncology NEWS International
- Oncology NEWS International Vol 12 No 1
- Volume 12
- Issue 1
First NCI Health Disparity Grants
BETHESDA, Maryland-Two medical facilities have received the first grants awarded by the National Cancer Institute’s Cooperative Planning Grant for Cancer Disparities Research Partnerships (CDRP). The 5-year, $27 million program provides support for radiation oncology clinical research at institutions that have not traditionally participated in NCI-sponsored studies. The two grants, totaling more than $2.5 million, went to the Rapid City Regional Hospital in South Dakota ($1,404,486), which serves a largely Native American population, and the Mercy Health Center, Laredo, Texas ($1,120,013), which serves a largely Hispanic community.
Advertisement
BETHESDA, MarylandTwo medical facilities have received the first grants awarded by the National Cancer Institute’s Cooperative Planning Grant for Cancer Disparities Research Partnerships (CDRP). The 5-year, $27 million program provides support for radiation oncology clinical research at institutions that have not traditionally participated in NCI-sponsored studies. The two grants, totaling more than $2.5 million, went to the Rapid City Regional Hospital in South Dakota ($1,404,486), which serves a largely Native American population, and the Mercy Health Center, Laredo, Texas ($1,120,013), which serves a largely Hispanic community.
Articles in this issue
almost 24 years ago
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launchedalmost 24 years ago
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLCalmost 24 years ago
Most Cancer Pain Is Experienced at the Patient’s Homealmost 24 years ago
HHS Unites Its HIV Advisorsalmost 24 years ago
Pain Therapy Improves Quality of Life for Caregiversalmost 24 years ago
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)almost 24 years ago
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Micealmost 24 years ago
Safe Handling Tips for Use of Testosterone Gelalmost 24 years ago
Lumpectomy/Mastectomy Equivalent in Early Breast Canceralmost 24 years ago
New Agent Tested in Refractory and Relapsed Ovarian CancerAdvertisement
Related to this article
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
2
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5